BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang X, Qi Y, Kong X, Zhai J, Li Y, Song Y, Wang J, Feng X, Fang Y. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment. Cancer Lett 2019;442:409-28. [PMID: 30419345 DOI: 10.1016/j.canlet.2018.10.042] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Pramanik SD, Kumar Halder A, Mukherjee U, Kumar D, Dey YN, R M. Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer. Front Chem 2022;10:948217. [DOI: 10.3389/fchem.2022.948217] [Reference Citation Analysis]
2 Zuo Y, Shen H, Sun F, Li P, Sun J, Kwok RTK, Lam JWY, Tang BZ. Aggregation-Induced Emission Luminogens for Cell Death Research. ACS Bio Med Chem Au 2022;2:236-57. [DOI: 10.1021/acsbiomedchemau.1c00066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Assumpção JAF, Pasquarelli-do-nascimento G, Duarte MSV, Bonamino MH, Magalhães KG. The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy. J Biomed Sci 2022;29. [DOI: 10.1186/s12929-022-00796-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Nakhjavani M, Shigdar S. Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer. Pharmacol Res 2021;175:106019. [PMID: 34861397 DOI: 10.1016/j.phrs.2021.106019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Sun X, Zhai J, Sun B, Parra ER, Jiang M, Ma W, Wang J, Kang AM, Kannan K, Pandurengan R, Zhang S, Solis LM, Haymaker CL, Raso MG, Mendoza Perez J, Sahin AA, Wistuba II, Yam C, Litton JK, Yang F. Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. Mod Pathol 2021. [PMID: 34839351 DOI: 10.1038/s41379-021-00973-w] [Reference Citation Analysis]
6 Wang M, Gu J, Zhang X, Yang J, Zhang X, Fang X. Long Non-coding RNA DANCR in Cancer: Roles, Mechanisms, and Implications. Front Cell Dev Biol 2021;9:753706. [PMID: 34722539 DOI: 10.3389/fcell.2021.753706] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Zhang W, Kong X, Ai B, Wang Z, Wang X, Wang N, Zheng S, Fang Y, Wang J. Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy. Front Oncol 2021;11:582664. [PMID: 34631507 DOI: 10.3389/fonc.2021.582664] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
8 Miao X, Guo Q, Pan Z, Xu X, Shao X, Wang X. The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer. Ann Transl Med 2021;9:1332. [PMID: 34532469 DOI: 10.21037/atm-21-3848] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Vito A, Salem O, El-Sayes N, MacFawn IP, Portillo AL, Milne K, Harrington D, Ashkar AA, Wan Y, Workenhe ST, Nelson BH, Bruno TC, Mossman KL. Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells. Commun Biol 2021;4:859. [PMID: 34253827 DOI: 10.1038/s42003-021-02375-9] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
10 Qi Y, Zhang L, Wang Z, Kong X, Zhai J, Fang Y, Wang J. Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence. Front Pharmacol 2021;12:653521. [PMID: 34267656 DOI: 10.3389/fphar.2021.653521] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Liu Q, Qi Y, Zhai J, Kong X, Wang X, Wang Z, Fang Y, Wang J. Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples. Front Immunol 2021;12:599207. [PMID: 34267742 DOI: 10.3389/fimmu.2021.599207] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Gupta N, Gaikwad S, Kaushik I, Wright SE, Markiewski MM, Srivastava SK. Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells. Int J Mol Sci 2021;22:5150. [PMID: 34068008 DOI: 10.3390/ijms22105150] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
13 Vito A, Rathmann S, Mercanti N, El-Sayes N, Mossman K, Valliant J. Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer. Int J Mol Sci 2021;22:4843. [PMID: 34063642 DOI: 10.3390/ijms22094843] [Reference Citation Analysis]
14 Luo W, Wang F, Luo H, Liu H. Arctigenin inhibits human breast cancer cell proliferation, migratory and invasive abilities and epithelial to mesenchymal transition by targeting 4EBP1. Exp Ther Med 2021;21:547. [PMID: 33850519 DOI: 10.3892/etm.2021.9979] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Qi Y, Chen L, Liu Q, Kong X, Fang Y, Wang J. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy. Front Immunol 2020;11:563258. [PMID: 33488573 DOI: 10.3389/fimmu.2020.563258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 Mediratta K, El-Sahli S, D'Costa V, Wang L. Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer. Cancers (Basel) 2020;12:E3529. [PMID: 33256070 DOI: 10.3390/cancers12123529] [Cited by in Crossref: 13] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
17 Chen Q, He Y, Wang Y, Li C, Zhang Y, Guo Q, Zhang Y, Chu Y, Liu P, Chen H, Zhou Z, Zhou W, Zhao Z, Li X, Sun T, Jiang C. Penetrable Nanoplatform for "Cold" Tumor Immune Microenvironment Reeducation. Adv Sci (Weinh) 2020;7:2000411. [PMID: 32995118 DOI: 10.1002/advs.202000411] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
18 Wang F, Cao X, Yin L, Wang Q, He Z. Identification of SCARA5 Gene as a Potential Immune-Related Biomarker for Triple-Negative Breast Cancer by Integrated Analysis. DNA Cell Biol 2020;39:1813-24. [PMID: 32816580 DOI: 10.1089/dna.2020.5449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Shi W, Tong Z, Qiu Q, Yue N, Guo W, Zou F, Zhou D, Li J, Huang W, Qian H. Novel HLA-A2 restricted antigenic peptide derivatives with high affinity for the treatment of breast cancer expressing NY-ESO-1. Bioorg Chem 2020;103:104138. [PMID: 32745760 DOI: 10.1016/j.bioorg.2020.104138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Tang L, Cai D, Qin M, Lu S, Hu MH, Ruan S, Jin G, Wang Z. Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy. ACS Omega 2020;5:726-34. [PMID: 31956823 DOI: 10.1021/acsomega.9b03381] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
21 Verdura S, Cuyàs E, Cortada E, Brunet J, Lopez-Bonet E, Martin-Castillo B, Bosch-Barrera J, Encinar JA, Menendez JA. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging (Albany NY) 2020;12:8-34. [PMID: 31901900 DOI: 10.18632/aging.102646] [Cited by in Crossref: 36] [Cited by in F6Publishing: 51] [Article Influence: 18.0] [Reference Citation Analysis]
22 Naik A, Monjazeb AM, Decock J. The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer. Front Immunol 2019;10:1940. [PMID: 31475003 DOI: 10.3389/fimmu.2019.01940] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
23 Singh S, Chakrabarti R. Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells. J Clin Med 2019;8:E642. [PMID: 31075939 DOI: 10.3390/jcm8050642] [Cited by in Crossref: 17] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
24 Tang C, Du Y, Liang Q, Cheng Z, Tian J. A selenium-containing selective histone deacetylase 6 inhibitor for targeted in vivo breast tumor imaging and therapy. J Mater Chem B 2019;7:3528-36. [DOI: 10.1039/c9tb00383e] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
25 He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res. 2018;37:327. [PMID: 30594216 DOI: 10.1186/s13046-018-1002-1] [Cited by in Crossref: 95] [Cited by in F6Publishing: 162] [Article Influence: 23.8] [Reference Citation Analysis]
26 Siddharth S, Sharma D. Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. Cancers (Basel) 2018;10:E514. [PMID: 30558195 DOI: 10.3390/cancers10120514] [Cited by in Crossref: 49] [Cited by in F6Publishing: 61] [Article Influence: 12.3] [Reference Citation Analysis]